← Back to Clinical Trials
Recruiting NCT06601842

NCT06601842 Monitoring and Optimization of Cerebral Perfusion Pressure in Post-cardiac Arrest Patients: a Pilot Study

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06601842
Status Recruiting
Phase
Sponsor National Taiwan University Hospital
Condition Cardiac Arrest
Study Type INTERVENTIONAL
Enrollment 50 participants
Start Date 2024-12-10
Primary Completion 2026-08

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
ICP monitoring

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 50 participants in total. It began in 2024-12-10 with a primary completion date of 2026-08.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this study is to establish the ICP and CPP monitoring process and analyze the results in post-arrest patients, to validate the correlation between direct and non-invasive ICP monitoring indicators, to establish a protocol of management of elevated ICP and insufficient CPP in post-arrest care, to establish a protocol for personalizing CPP and MAP optimization, and to analyze its impact on neuroprognosis. Participants will receive ICP monitoring within 12 hours post-ROSC if meet all inclusion and exclusion criteria.

Eligibility Criteria

Inclusion Criteria: * non-traumatic cardiac arrest * admitted to ICU * GCS: motor \<=5 * severity: TIMECARD score medium-risk group Exclusion Criteria: * traumatic cardiac arrest * pregnancy * intracranial hemorrhage * coagulopathy * anti-platelet or anti-coagulation use * terminal illness * pre-arrest CPC score \>=3 * GWR \< 1.2 on CT or severe hypoxic ischemic encephalopathy * CNS infection

Contact & Investigator

Central Contact

Dean-An Ling, MD

✉ speckle0714@gmail.com

📞 +886-02-23123456

Principal Investigator

Dean-An Ling, MD

STUDY DIRECTOR

National Taiwan University Medical College and Hospital

Frequently Asked Questions

Who can join the NCT06601842 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Cardiac Arrest. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06601842 currently recruiting?

Yes, NCT06601842 is actively recruiting participants. Contact the research team at speckle0714@gmail.com for enrollment information.

Where is the NCT06601842 trial being conducted?

This trial is being conducted at Taipei, Taiwan.

Who is sponsoring the NCT06601842 clinical trial?

NCT06601842 is sponsored by National Taiwan University Hospital. The principal investigator is Dean-An Ling, MD at National Taiwan University Medical College and Hospital. The trial plans to enroll 50 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology